MarketCap
Facebook
X
TelegramGeschäftsbericht 2025
hinzugefügt 23.03.2026
Arbutus Biopharma Corporation Langfristiger Schuldenstrom 2011-2026 | ABUS
Langfristiger Schuldenstrom Jährlich Arbutus Biopharma Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 547 K | 483 K | 425 K | 372 K | 383 K | 390 K | 340 K | - | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 547 K | 340 K | 420 K |
Langfristiger Schuldenstrom anderer Aktien in der Pharmaeinzelhändler
| Name | Langfristiger Schuldenstrom | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
3.63 M | - | 2.43 % | $ 254 M |  Germany |
 |
Aquestive Therapeutics
AQST
|
631 K | $ 4.14 | 0.36 % | $ 443 M |  USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
4.21 M | $ 8.41 | 4.73 % | $ 230 M |  Israel |
 |
Ardelyx
ARDX
|
1.48 M | $ 6.06 | 1.94 % | $ 1.46 B | USA |
 |
argenx SE
ARGX
|
10.8 M | $ 752.35 | 0.79 % | $ 25 B |  Niderland |
 |
Arcutis Biotherapeutics
ARQT
|
294 K | $ 23.83 | 0.85 % | $ 3.03 B | USA |
 |
Aytu BioScience
AYTU
|
137 K | $ 2.65 | -1.12 % | $ 16.6 M | USA |
 |
I-Mab
IMAB
|
8.06 M | - | - | $ 866 M |  China |
 |
BioCardia
BCDA
|
442 K | $ 1.2 | -0.04 % | $ 8 M | USA |
 |
BioCryst Pharmaceuticals
BCRX
|
937 K | $ 9.6 | 6.37 % | $ 1.98 B | USA |
 |
Acorda Therapeutics
ACOR
|
1.59 M | - | -24.86 % | $ 820 K | USA |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
675 K | $ 9.48 | -3.27 % | $ 613 M | USA |
 |
BioVie
BIVI
|
74.5 K | $ 1.45 | 2.09 % | $ 2.14 M | USA |
 |
Adverum Biotechnologies
ADVM
|
5.67 M | - | - | $ 86.2 M | USA |
 |
Advaxis
ADXS
|
166 K | - | -9.65 % | $ 45.9 M | USA |
 |
Applied Molecular Transport
AMTI
|
4.64 M | - | - | $ 10.1 M | USA |
 |
Aeterna Zentaris
AEZS
|
271 K | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
181 K | - | -10.17 % | $ 12.2 K | USA |
 |
AIkido Pharma
AIKI
|
554 K | - | 1.93 % | $ 17.4 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
625 K | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
1.27 M | - | - | $ 26.5 M | USA |
 |
Akouos
AKUS
|
671 K | - | 0.23 % | $ 488 M | USA |
 |
BioLineRx Ltd.
BLRX
|
522 K | $ 2.32 | 4.98 % | $ 908 M | Israel |
 |
BioMarin Pharmaceutical
BMRN
|
8.57 M | $ 56.49 | 1.78 % | $ 10.8 B | USA |
 |
BioNTech SE
BNTX
|
45 M | $ 92.3 | 1.23 % | $ 27.2 B | Germany |
 |
Allena Pharmaceuticals
ALNA
|
317 K | - | 3.16 % | $ 1.9 M | USA |
 |
Alpine Immune Sciences
ALPN
|
756 K | - | - | $ 2.17 B | USA |
 |
Aileron Therapeutics
ALRN
|
48 K | - | 10.36 % | $ 9.8 M | USA |
 |
BioXcel Therapeutics
BTAI
|
65 K | $ 1.16 | -2.12 % | $ 14.2 M | USA |
 |
Cabaletta Bio
CABA
|
3.46 M | $ 3.2 | 7.94 % | $ 322 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
43 K | $ 3.21 | 4.56 % | $ 6.98 B | Israel |
 |
Aravive
ARAV
|
2.2 M | - | -13.39 % | $ 1.45 M | USA |
 |
Catalyst Biosciences
CBIO
|
636 K | $ 19.97 | 2.94 % | $ 1.78 B | USA |
 |
Aptose Biosciences
APTO
|
193 K | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
337 K | - | -39.0 % | $ 4.57 M | USA |
 |
Codexis
CDXS
|
2.94 M | $ 1.97 | 7.97 % | $ 172 M | USA |
 |
Cerus Corporation
CERS
|
2.9 M | $ 1.91 | 2.42 % | $ 364 M | USA |
 |
Cullinan Management
CGEM
|
780 K | $ 15.4 | 6.72 % | $ 928 M | USA |
 |
Coherus BioSciences
CHRS
|
1.83 M | $ 1.75 | 0.87 % | $ 205 M | USA |
 |
CureVac N.V.
CVAC
|
3.47 M | - | - | $ 867 M | Germany |
 |
AstraZeneca PLC
AZN
|
382 M | - | - | $ 96.9 B |  Britain |